Steven R. DeMeester, M.D.
disclosures–22 sec
BE incidence–30 sec http://www.ncbi.nlm.nih.gov/pubmed/15366737
HGD–1:18
issues to consider–2:25
endotherapy candidates–2:44
low risk submucosal invasion–3:31 http://www.
Keyword(s): AIM II, BE, cryospray ablation, CSA Medical, depth of invasion, EGD, en-bloc resection, endoscopic resection, endoscopic tx, endotherapy, esophageal adenocarcinoma, esophagectomy, EUS, Halo 360, HGD, IM, intramucosal cx, lap Nissen, LGD, LN metastases, NBI, reflux, RFA, surveillance, UE, VSE
SAGES Member Discussion
This talk appeared at the 2011 SAGES Meeting and was selected via a peer review process
Leave a Comment
You must be logged in to post a comment.
